Navigation Links
Experimental agent blocks prostate cancer in animal study
Date:5/22/2008

COLUMBUS, Ohio An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows.

The agent, OSU-HDAC42, belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate genes that normally protect against cancer but are turned off by the cancer process.

The study, conducted by the Ohio State University Comprehensive Cancer Center researchers who also developed the drug, showed that the agent kept mice with a precancerous condition from developing advanced prostate cancer.

Instead, the animals either remained at the precancerous stage, called prostatic intraepithelial neoplasia (PIN), or they developed benign enlargements of the prostate called adenomas. The main side effect of the treatment was a reversible shrinkage of the testicles.

Of the animals not given the drug, 74 percent developed advanced prostate cancer.

The findings are reported in the May 15 issue of the journal Cancer Research. Human testing of the compound is expected to begin early next year.

This study shows that an agent with a specific molecular target can dramatically inhibit prostate cancer development in an aggressive model of the disease, says coauthor Dr. Steven Clinton, director of the prostate and genitourinary oncology clinic at Ohio States James Cancer Hospital and Solove Research Institute. We hope to see this agent in clinical trials soon and ultimately used for prostate-cancer prevention or therapy.

Furthermore, when the drug treatment was stopped after 24 weeks, two of the animals were followed for an additional 18 weeks. The animals developed adenomas but were alive after 42 weeks, well beyond their normal 32-week life span.

The drug not only kept the animals cancer free, but also prolonged their life span, says Ching-Shih Chen, who led the drugs development and the new study at the Comprehensive Cancer Center. Chen is also professor of pharmacy and of internal medicine.

A veterinary pathologist on the study, first author Aaron Sargeant, graduate research associate in veterinary biosciences, was intrigued that adenomas occurred in the treated animals. Adenomas are not commonly found to be part of prostate-cancer development in this system, he says. This drug appears to shift tumor progression from its usual aggressive course to a more benign direction.

For this study, Chen, Sargeant, Clinton and their colleagues used a strain of transgenic mice that develops PIN at about six weeks of age, then progresses to advanced prostate cancer by 24 to 32 weeks.

The researchers added the drug to the diet of 23 of the cancer-prone mice beginning at six weeks of age, when the animals develop the precancerous condition, and continued the treatment for 18 weeks.

They then examined the animals. Of the treated mice, one showed signs of early stage cancer, but 12 still had only the precancerous condition and 10 had adenomas.

In contrast, 17 of 23 control animals developed advanced prostate cancer, two had early stage cancer, three had the precancerous condition and one an adenoma.

Experiments using a nontransgenic strain of the same mouse they do not develop prostate cancer showed that the degeneration of the testicles that accompanied the drug treatment was reversible when the drug treatment stops.

Chen noted that 186,320 cases of prostate cancer are expected this year, with 28,660 deaths from the disease. Our findings are very exciting, considering that an agent capable of reducing prostate-cancer risk by only 10 percent could prevent 18,600 cases of the disease in the United States each year, Chen says.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Experimental Drug Eases Symptoms of Mild Alzheimers
2. Experimental Blood Substitutes Unsafe, Study Finds
3. Honda to Showcase Experimental Walking Assist Device
4. Experimental Alzheimers Drug Shows Promise
5. Experimental drug shows promise in treating certain lymphomas
6. Experimental Cancer Vaccines Show Promise
7. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
8. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
9. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
10. 52 minority scientists receive travel fellowships to Experimental Biology 2008
11. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
(Date:10/4/2017)... Mass. , Oct. 4, 2017 ... of single-use, self-contained, illuminating medical devices, today announced ... National Health Surveillance Agency (or Agência Nacional de ... The first single-use, cordless surgical retractor with integrated ... provides optimal access, illumination and exposure of a ...
Breaking Medicine Technology: